ReviewMolecular immunology2014
Genetic variants in the complement system predisposing to age-related macular degeneration: a review.
Review in Molecular immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 1 synthesis or guideline pooled it, 117 citations in OpenAlex.
- Efficacy and safety of complement inhibitors in patients with geographic atrophy associated with age-related macular degeneration: a network meta-analysis of randomized controlled trials.Frontiers in pharmacology · 2024Pooled it
- Adherence to a Mediterranean diet, genetic susceptibility, and progression to advanced macular degeneration: a prospective cohort study.The American journal of clinical nutrition · 2015Trial
- Identification of novel blood-borne soluble binding partners of factor H-related proteins.Scientific reports · 2026Article
- In-Depth Analysis of the Intravitreal Biocompatibility of Polyethylene Glycol of Different Molecular Weight in an In Vivo Porcine Model.Investigative ophthalmology & visual science · 2026Article
- Family History of Age-Related Macular Degeneration and Genetics Predict Progression to Advanced Age-Related Macular Degeneration Adjusting for Macular Status, Demographic, and Lifestyle Factors.American journal of ophthalmology · 2023Article
- Rare DysfunctionalOphthalmology science · 2023Article
- Role of Complement in the Onset of Age-Related Macular Degeneration.Biomolecules · 2023Review
- Physiology and pathology of the C3 amplification cycle: A retrospective.Immunological reviews · 2023Review
- Alternative pathway activation: Ever ancient and ever new.Immunological reviews · 2023Review
- Protein therapeutics and their lessons: Expect the unexpected when inhibiting the multi-protein cascade of the complement system.Immunological reviews · 2023Review
- Purinergic signaling via P2X receptors and mechanisms of unregulated ATP release in the outer retina and age-related macular degeneration.Frontiers in neuroscience · 2023Review
- Application of Machine Learning to Ranking Predictors of Anti-VEGF Response.Life (Basel, Switzerland) · 2022Article
- Common complement factor H polymorphisms are linked with periodontitis in elderly patients.Journal of periodontology · 2022Article
- Functional analysis of rare genetic variants in complement factor I in advanced age-related macular degeneration.Human molecular genetics · 2022Article
- Evaluating a Causal Relationship between Complement Factor I Protein Level and Advanced Age-Related Macular Degeneration Using Mendelian Randomization.Ophthalmology science · 2022Article
- Novel Epigenetic Clock Biomarkers of Age-Related Macular Degeneration.Frontiers in medicine · 2022Article
- Article
- Molecular Mechanisms of Retinal Pigment Epithelium Dysfunction in Age-Related Macular Degeneration.International journal of molecular sciences · 2021Review
- FHL-1 interacts with human RPE cells through the α5β1 integrin and confers protection against oxidative stress.Scientific reports · 2021Article
- Investigational Agents in Development for the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2021Review
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
Abstract
Age-related macular degeneration (AMD) is a major cause of visual impairment in the western world. It is characterized by the presence of lipoproteinaceous deposits (drusen) in the inner layers of the retina. Immunohistochemistry studies identified deposition of complement proteins in the drusen as well as in the choroid. In the last decade, genetic studies have linked both common and rare variants in genes of the complement system to increased risk of development of AMD. Here, we review the variants described to date and discuss the functional implications of dysregulation of the alternative pathway of complement in AMD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.